Surgery improves overall and cancer-specific survival of rare urinary cancers; population - based study

ElsevierVolume 44, September 2022, 101807Surgical OncologyHighlights•

Rare UT cancer lack adequate understanding of survival and therapeutic options.

Multimodality therapeutic approach on rare UT cancer OS and CSS were compared.

OS outperformed CSS in the locoregional stage.

OS and CSS groups of the locoregional stage showed better survival after surgery.

Abstract

Numerous rare urinary tract (UT) cancers lack adequate understanding of survival and therapeutic options, and nearly all responses to systemic therapy are unsatisfactory, yet clinical research is scarce.

Methods

Between 2010 and 2015, a total of (14,622 patients) with uncommon UT cancer (62.5%) in the overall survival (OS) group and (37.5%) in the cancer specific survival (CSS)group were identified in the SEER database. multimodality therapeutic approach on OS and CSS were compared.

Results

In uncommon UT malignancies, OS outperformed CSS in the locoregional stage (P < 0.05), but not in the distant stage (P = 0.34). Non-performed surgery had poor survival in both OS (HR 1.647; 95% CI (1.461–1.856)) and CSS (HR 1.573; 95% CI (1.399–1.769)) respectively (P < 0.05). There were no significant differences in survival in the CSS group between those who received or did not obtain chemotherapy.

Conclusions

The OS group survives substantially longer than the CSS group in the locoregional stage, but not at the distant stage. While both the OS and CSS groups of the locoregional stage were linked with improved survival after surgery, chemotherapy treatment decreased OS but not CSS in patients with uncommon urological cancers. There were no differences in radiation between the OS and CSS.

Keywords

Rare urinary cancer

Overall survival

Cancer-specific survival

Epidemiology

AbbreviationsCSS

Cancer-Specific Survival

SEER

Surveillance, Epidemiology, and End Results Database

PSM

Propensity Score Matching Study

© 2022 The Authors. Published by Elsevier Ltd.

留言 (0)

沒有登入
gif